{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T16:37:51Z","timestamp":1782319071475,"version":"3.54.5"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T00:00:00Z","timestamp":1641945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Cardiovascular involvement is among the main features of MPS disorders and it is also a significant cause of morbidity and mortality. The range of manifestations includes cardiac valve disease, conduction abnormalities, left ventricular hypertrophy, and coronary artery disease. Here, we assessed the cardiovascular manifestations in a cohort of children and adults with MPS I, II, IV, and VI, as well as the impact of enzyme replacement therapy (ERT) on those manifestations.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We performed a chart review of 53 children and 23 adults with different types of MPS that had performed echocardiograms from January 2000 until October 2018. Standardized Z scores were obtained for heart chamber sizes according to the body surface area. When available, echocardiographic measurements that were performed before ERT and at least 18 months after that date were used for the assessment of pre- and post-treatment parameters.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Left side valvular disease was a frequent finding, with mitral and aortic thickening being reported in most patients in all four MPS types. Left atrium dilatation was present in 26% of the patients; 25% had increased relative wall thickness; 28% had pulmonary hypertension. The cardiovascular involvement was, in general, more prevalent and more severe in adults than in children, including conduction disorders (40 vs. 16%), mitral stenosis (26 vs. 6%), aortic stenosis (13 vs. 4%), and systolic dysfunction (observed in only one adult patient). ERT promoted a significant reduction of the left ventricular hypertrophy parameters, but failed to improve valve abnormalities, pulmonary hypertension, and left atrial dilatation.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> Adult patients with MPS may develop severe cardiovascular involvement, not commonly observed in children, and clinicians should be aware of the need for careful monitoring and timely management of those potentially life-threatening complications. Our results also confirm the impact of long-term ERT on left ventricular hypertrophy and its limitations in reversing other prevalent cardiovascular manifestations.<\/jats:p>","DOI":"10.3389\/fcvm.2021.801147","type":"journal-article","created":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T06:50:48Z","timestamp":1641970248000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Progression of Cardiovascular Manifestations in Adults and Children With Mucopolysaccharidoses With and Without Enzyme Replacement Therapy"],"prefix":"10.3389","volume":"8","author":[{"given":"Fabiano de Oliveira","family":"Poswar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hallana Souza","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Barreto Santiago","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solano Vinicius","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina Fischinger Moura de","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Giugliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme","family":"Baldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3390\/diagnostics10030172","article-title":"Diagnosis of mucopolysaccharidoses","volume":"10","author":"Kubaski","year":"2020","journal-title":"Diagnostics."},{"key":"B2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ymgme.2018.01.003","article-title":"Clinical presentation and diagnosis of mucopolysaccharidoses","volume":"125","author":"Stapleton","year":"2018","journal-title":"Mol Genet Metab."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s10545-011-9359-8","article-title":"Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management","volume":"34","author":"Braunlin","year":"2011","journal-title":"J Inherit Metab Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.carpath.2017.01.001","article-title":"Progressive heart disease in mucopolysaccharidosis type I mice may be mediated by increased cathepsin B activity","volume":"27","author":"Baldo","year":"2017","journal-title":"Cardiovasc Pathol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.3390\/ijms21082975","article-title":"Intravenous enzyme replacement therapy in mucopolysaccharidoses: clinical effectiveness and limitations","volume":"21","author":"Parini","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s00380-018-1242-1","article-title":"Aortic root dilatation in patients with mucopolysaccharidoses and the impact of enzyme replacement therapy","volume":"34","author":"Poswar F de","year":"2019","journal-title":"Heart Vessels."},{"key":"B7","doi-asserted-by":"publisher","first-page":"232640981875580","DOI":"10.1177\/2326409818755800","article-title":"Long-term galsulfase treatment associated with improved survival of patients with mucopolysaccharidosis vi (maroteaux-lamy syndrome)","volume":"6","author":"Quartel","year":"2018","journal-title":"J Inborn Errors Metab Screen."},{"key":"B8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/S0022-3476(78)80601-5","article-title":"Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults","volume":"93","author":"Haycock","year":"1978","journal-title":"J Pediatr."},{"key":"B9","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/0002-9149(86)90771-X","article-title":"Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings","volume":"57","author":"Devereux","year":"1986","journal-title":"Am J Cardiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e006979","DOI":"10.1161\/CIRCIMAGING.117.006979","article-title":"Relationship of echocardiographic Z scores adjusted for body surface area to age, sex, race, and ethnicity","volume":"10","author":"Lopez","year":"2017","journal-title":"Circ Cardiovasc Imaging."},{"key":"B11","first-page":"61","article-title":"Structural measurements and adjustments for growth","volume-title":"Echocardiography in Pediatric and Congenital Heart Disease","author":"Sluysmans","year":""},{"key":"B12","unstructured":"BCH Z-Score Calculator - Home"},{"key":"B13","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10545-013-9649-4","article-title":"Mucopolysaccharidosis VI: cardiac involvement and the impact of enzyme replacement therapy","volume":"37","author":"Kampmann","year":"2014","journal-title":"J Inherit Metab Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/0002-9149(76)90491-4","article-title":"Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence or absence of asynergy","volume":"37","author":"Teichholz","year":"1976","journal-title":"Am J Cardiol."},{"key":"B15","first-page":"353","article-title":"An analysis of the time relations of electrocardiograms","volume":"7","author":"Bazett","year":"1920","journal-title":"Heart."},{"key":"B16","doi-asserted-by":"publisher","first-page":"S110","DOI":"10.1016\/j.ymgme.2016.11.280","article-title":"Aortic root dilatation in patients with mucopolysaccharidoses and the effect of enzyme replacement therapy","volume":"120","author":"Poswar","year":"2017","journal-title":"Mol Genet Metab."},{"key":"B17","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1017\/S104795110999062X","article-title":"Echocardiographic study of paediatric patients with mucopolysaccharidosis","volume":"20","author":"Leal","year":"2010","journal-title":"Cardiol Young."},{"key":"B18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2143\/AC.60.1.2005049","article-title":"Cardiovascular changes in mucopolysaccharidoses in Taiwan","volume":"60","author":"Chen","year":"2005","journal-title":"Acta Cardiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e0162612","DOI":"10.1371\/journal.pone.0162612","article-title":"Heart and cardiovascular involvement in patients with mucopolysaccharidosis type IVA (Morquio-A Syndrome)","volume":"11","author":"Kampmann","year":"2016","journal-title":"PLoS ONE."},{"key":"B20","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s10545-011-9410-9","article-title":"Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP)","volume":"36","author":"Hendriksz","year":"2013","journal-title":"J Inherit Metab Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s10545-014-9686-7","article-title":"Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe phenotype: an international case series","volume":"37","author":"Lampe","year":"2014","journal-title":"J Inherit Metab Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ymgmr.2016.04.003","article-title":"Long-term galsulfase enzyme replacement therapy in Taiwanese mucopolysaccharidosis VI patients: a case series","volume":"7","author":"Lin","year":"2016","journal-title":"Mol Genet Metab Rep."},{"key":"B23","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.amjcard.2006.02.047","article-title":"Cardiac findings after enzyme replacement therapy for mucopolysaccharidosis type I","volume":"98","author":"Braunlin","year":"2006","journal-title":"Am J Cardiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s10545-012-9481-2","article-title":"Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme\u00ae) therapy","volume":"36","author":"Braunlin","year":"2013","journal-title":"J Inherit Metab Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ymgme.2016.02.003","article-title":"Cardiac structure and function and effects of enzyme replacement therapy in patients with mucopolysaccharidoses I, II, IVA and VI","volume":"117","author":"Lin","year":"2016","journal-title":"Mol Genet Metab."},{"key":"B26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12881-016-0284-4","article-title":"12year follow up of enzyme-replacement therapy in two siblings with attenuated mucopolysaccharidosis I: the important role of early treatment","volume":"17","author":"Gabrielli","year":"2016","journal-title":"BMC Med Genet."},{"key":"B27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ymgme.2013.03.005","article-title":"Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice","volume":"109","author":"Baldo","year":"2013","journal-title":"Mol Genet Metab."},{"key":"B28","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13052-018-0560-3","article-title":"Early diagnosis and management of cardiac manifestations in mucopolysaccharidoses: a practical guide for paediatric and adult cardiologists","volume":"44","author":"Boffi","year":"2018","journal-title":"Ital J Pediatr."},{"key":"B29","doi-asserted-by":"publisher","first-page":"632293","DOI":"10.3389\/fped.2021.632293","article-title":"Hypertrophic cardiomyopathy in children: pathophysiology, diagnosis, and treatment of non-sarcomeric causes","volume":"9","author":"Monda","year":"2021","journal-title":"Front Pediatr."},{"key":"B30","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/8904_2012_141","article-title":"The transforming growth factor-Beta signaling pathway involvement in cardiovascular lesions in mucopolysaccharidosis-I","volume":"7","author":"Yano","year":"2013","journal-title":"JIMD Rep."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1136\/heartjnl-2015-309258","article-title":"Cardiac issues in adults with the mucopolysaccharidoses: current knowledge and emerging needs","volume":"102","author":"Braunlin","year":"2016","journal-title":"Heart Br Card Soc."},{"key":"B32","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1203\/00006450-199408000-00009","article-title":"Bone marrow transplantation has a significant effect on enzyme levels and storage of glycosaminoglycans in tissues and in isolated hepatocytes of mucopolysaccharidosis type VII mice","volume":"36","author":"Poorthuis","year":"1994","journal-title":"Pediatr Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1203\/01.pdr.0000190579.24054.39","article-title":"Cardiac functional and histopathologic findings in humans and mice with mucopolysaccharidosis type I: implications for assessment of therapeutic interventions in hurler syndrome","volume":"59","author":"Braunlin","year":"2006","journal-title":"Pediatr Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1161\/01.CIR.54.4.553","article-title":"Left atrial enlargement. Echocardiographic assessment of electrocardiographic criteria","volume":"54","author":"Waggoner","year":"1976","journal-title":"Circulation."},{"key":"B35","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13023-018-0883-6","article-title":"Cardiac features and effects of enzyme replacement therapy in Taiwanese patients with Mucopolysaccharidosis IVA Dr. Segolene Ayme","volume":"13","author":"Lin","year":"2018","journal-title":"Orphanet J Rare Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.3390\/ijms17122004","article-title":"Aortic root dilatation in mucopolysaccharidosis I-VII","volume":"17","author":"Bolourchi","year":"2016","journal-title":"Int J Mol Sci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1161\/01.CIR.53.2.268","article-title":"Echocardiographic determination of left atrial volumes in children with congenital heart disease","volume":"53","author":"Yabek","year":"1976","journal-title":"Circulation."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1002\/ajmg.a.33902","article-title":"Sleep abnormalities in untreated patients with mucopolysaccharidosis type VI","volume":"155","author":"John","year":"2011","journal-title":"Am J Med Genet A."},{"key":"B39","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s12574-018-0373-9","article-title":"Left atrial dilatation in systolic heart failure: a marker of poor prognosis, not just a buffer between the left ventricle and pulmonary circulation","volume":"16","author":"Rossi","year":"2018","journal-title":"J Echocardiogr."},{"key":"B40","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ymgme.2009.08.006","article-title":"Japan Elaprase\u00ae treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II)","volume":"99","author":"Okuyama","year":"2010","journal-title":"Mol Genet Metab."},{"key":"B41","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ymgmr.2015.03.011","article-title":"Enzymatic replacement therapy for Hunter disease: up to 9 years experience with 17 patients","volume":"3","author":"Parini","year":"2015","journal-title":"Mol Genet Metab Rep."},{"key":"B42","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ymgme.2020.03.005","article-title":"Cardiac rhythm abnormalities - an underestimated cardiovascular risk in adult patients with Mucopolysaccharidoses","volume":"130","author":"Ayuna","year":"2020","journal-title":"Mol Genet Metab."},{"key":"B43","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/jimd.12015","article-title":"Cardiac disease in mucopolysaccharidosis type III","volume":"42","author":"Nijmeijer","year":"2019","journal-title":"J Inherit Metab Dis."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.801147\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T06:50:55Z","timestamp":1641970255000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.801147\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,12]]},"references-count":43,"alternative-id":["10.3389\/fcvm.2021.801147"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2021.801147","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,12]]},"article-number":"801147"}}